MARKET

RCUS

RCUS

ARCUS BIOSCIENCE
NYSE

Real-time Quotes | Nasdaq Last Sale

20.50
-0.23
-1.11%
After Hours: 20.50 0 0.00% 16:09 10/28 EDT
OPEN
20.26
PREV CLOSE
20.73
HIGH
21.08
LOW
19.55
VOLUME
503.71K
TURNOVER
--
52 WEEK HIGH
37.41
52 WEEK LOW
7.19
MARKET CAP
1.33B
P/E (TTM)
-8.3999
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SRRK, SYNL, KTCC and SUM among after-hours movers
Gainers: [[SRRK]] +23.7%. [[SYNL]] +12.3%. [[CYH]] +11.6%. [[FSLR]] +8.8%. [[MSTR]] +7.1%.Losers: [[KTCC]] -12.8%. [[SUM]] -8.7%. [[RCUS]] -8.3%. [[BGFV]] -6.0%. [[APLT]] -5.8%.
Seekingalpha · 1d ago
Arcus Biosciences (NYSE:RCUS) Shareholders Have Enjoyed An Impressive 119% Share Price Gain
While Arcus Biosciences, Inc. (NYSE:RCUS) shareholders are probably generally happy, the stock hasn't had particularly...
Simply Wall St. · 10/20 18:20
Jennifer Jarrett returns to Arcus Biosciences as COO
Arcus Biosciences (RCUS) announces that Jennifer Jarrett has rejoined Arcus as COO with responsibility for Arcus's commercial and general & administrative organizations, including finance and human resources.Ms. Jarrett has served
Seekingalpha · 10/02 10:54
Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarrett has rejoined Arcus as Chief Operating Officer with responsibility for Arcus’s commercial and general & administrative organizations
Business Wire · 10/01 21:41
Hedge Funds Keep Buying Arcus Biosciences, Inc. (RCUS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 09/28 18:43
Arcus Biosciences (RCUS) Investor Presentation - Slideshow
The following slide deck was published by Arcus Biosciences, Inc. in conjunction with this event.
Seekingalpha · 09/18 19:24
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Gilead announces another cancer deal
Shares of Gilead Sciences Inc. undefined gained 0.3% in premarket trading on Tuesday after the drugmaker on Monday evening announced a deal worth more than...
MarketWatch · 08/18 13:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCUS. Analyze the recent business situations of ARCUS BIOSCIENCE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RCUS stock price target is 38.67 with a high estimate of 48.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 167
Institutional Holdings: 41.88M
% Owned: 64.53%
Shares Outstanding: 64.91M
TypeInstitutionsShares
Increased
48
13.31M
New
69
4.63M
Decreased
24
3.46M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-2.08%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Terry Rosen
President/Co-Founder/Director
Juan Jaen
Chief Financial Officer/Chief Accounting Officer
Robert Goeltz
Chief Operating Officer/Director
Jennifer Jarrett
Vice President - Finance
Jason Barker
Other
William Grossman
Other
Steven Chan
Other
Eric Hoefer
Lead Director/Independent Director
Yasunori Kaneko
Director
David Lacey
Director
Patrick Machado
Director
Merdad Parsey
Director
Antoni Ribas
Independent Director
Kathryn Falberg
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arcus Biosciences Inc stock information, including NYSE:RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.